Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers—A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference

Gastric, esophageal and gastro-esophageal junction cancers are associated with inferior outcomes. For early-stage disease, perioperative chemotherapy or chemoradiation followed by surgery is the standard treatment. For most patients with advanced upper gastrointestinal tract cancers, platinum-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, Karen, Lim, Howard, Ravi, Deepti, Ahmed, Shahida, Brunet, Bryan, Davies, Janine, Doll, Corinne, Dueck, Dorie-Anna, Gordon, Vallerie, Hebbard, Pamela, Kim, Christina A., Le, Duc, Lee-Ying, Richard, McGhie, John Paul, Park, Jason, Renouf, Daniel J., Schellenberg, Devin, Wong, Ralph P. W., Zaidi, Adnan, Ahmed, Shahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139288/
https://www.ncbi.nlm.nih.gov/pubmed/35621647
http://dx.doi.org/10.3390/curroncol29050257
Descripción
Sumario:Gastric, esophageal and gastro-esophageal junction cancers are associated with inferior outcomes. For early-stage disease, perioperative chemotherapy or chemoradiation followed by surgery is the standard treatment. For most patients with advanced upper gastrointestinal tract cancers, platinum-based chemotherapy remains a standard treatment. Recently, several randomized clinical trials have demonstrated the benefit of immunotherapy involving checkpoint inhibitors alone or in combination with chemotherapy in patients with gastro-esophageal cancer and have changed the treatment landscape. The Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC), involving experts from four Western Canadian provinces, convened virtually on 16 June 2021 and developed the recommendations on the role of immunotherapy in patients with gastro-esophageal cancer.

Ejemplares similares